Optimal treatment for relapsing patients with Hodgkin lymphoma.

Abstract

Relapsed or refractory classical Hodgkin lymphoma (HL) remains a therapeutic challenge. Patients with relapsed HL should be identified according to their prognostic factors at relapse (duration of remission and extranodal disease or stage). Patients with refractory disease, defined as progression during induction treatment or within 90 days after the end of… (More)
DOI: 10.1586/ehm.09.12

Topics

  • Presentations referencing similar topics